VPC
VRNA

Vestal Point Capital’s Verona Pharma VRNA Stock Holding History

Vestal Point Capital’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-267,627
Closed -$17M – 85
2025
Q1 		$17M Sell
267,627
-227,373
-46% -$13.6M 1.21% 29
2024
Q4 		$23M Buy
+495,000
New +$18.6M 1.36% 29

Other funds holding VRNA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vestal Point Capital's VRNA Position: Q2 2025 in Review

Vestal Point Capital sold out of Verona Pharma (VRNA) in Q2 2025, closing a stake of 267,627 shares — an estimated $17M sold.

Vestal Point Capital first reported a position in VRNA in Q4 2024 and held it in 2 quarters. The position peaked at $23M in Q4 2024. 292 funds tracked by Wall St. Rank hold VRNA as of Q2 2025.

  • Vestal Point Capital reported no remaining Verona Pharma position as of Q2 2025 after selling out during the quarter.
  • Vestal Point Capital sold 267,627 Verona Pharma shares in Q2 2025, an estimated $17M.
  • Vestal Point Capital first reported a position in Verona Pharma in Q4 2024 and held it in 2 quarters.
  • Vestal Point Capital's Verona Pharma position peaked at $23M in Q4 2024.
  • 292 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2025.

Based on Vestal Point Capital's 13F filing for Q2 2025, filed 14 Aug 2025.